Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / MOR - MorphoSys FDA Approval And Other News: The Good Bad And Ugly Of Biopharma

MOR - MorphoSys FDA Approval And Other News: The Good Bad And Ugly Of Biopharma

MorphoSys AG

MorphoSys receives FDA approval for Monjuvi

MorphoSys AG (MOR) announced that the FDA has approved the use of Monjuvi in conjunction with lenalidomide, for treating adult patients suffering from relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL concerning low grade lymphoma, and who do not qualify for autologous stem cell transplant. The company is collaborating with Incyte (INCY) for developing this drug candidate.

Monjuvi is the first FDA approval for a second-line treatment for adult patients with the condition. Jean-Paul Kress, M.D., Chief Executive Officer, MorphoSys said “This approval marks

Read more ...
Stock Information
Company Name: MorphoSys AG
Stock Symbol: MOR
Market: NASDAQ
Website: morphosys.com
Menu
MOR MOR Quote MOR Short MOR News MOR Articles MOR Message Board
Get MOR Alerts

News, Short Squeeze, Breakout and More Instantly...